You have read all your free articles, to continue reading subscribe to read the rest of this content.
The last few months have been very eventful for LIDDS; the last patient has been enrolled in their localized treatment of prostate cancer study and they are evaluating a possible listing on Nasdaq Stockholm’s Main Market. The CEO of LIDDS, Monica Wallter, gives us an update. What’s next for LAlready…
Swedish biotech company Cantargia recently presented its 2017 Q2 results and it looks like they are ready for their next step, taking them from preclinical to clinical stage. One of the company’s most recent achievements, after the end of Q2, was the patient recruitment to its CANFOUR study. ThAlready a…
When is the right time to list your firm on themarket? Marie Parck, responsible for listings at NASDAQ OMX Stockholm, unravels the terms, steps and conditions of the stock exchange. What does it take to be introduced on the stock market? “At NASDAQ OMX we provide two different offers. One…
Iris Öhrn considers herself a cosmopolitan person, and with good reason. The investment advisor for life science at Business Region Göteborg left her native Cuba to study and work abroad before settling in Sweden. While up until recently, most of Iris Öhrn’s goals were professional, now she Already a subscriber…
